USA – Tr1X, a San Diego, CA-based biotechnology company focused on engineering cures for immune and inflammatory diseases, raised $75M in Series A funding.
The round was led by The Column Group, with participation from NEVA SGR and Alexandria Ventures. The company intends to use the funds to enable immediate and expedited execution to advance its proprietary pipeline of first-of-their kind allogeneic engineered Treg and CAR-Treg cell therapies to treat major autoimmune diseases affecting millions of patients worldwide. Tr1X is a biotechnology company focused on engineering cures for immune and inflammatory diseases. Its pipeline of allogeneic cell therapies is being developed for diseases with high unmet medical need. Currently, the company is working on its first investigational Tr1 cell therapy, TRX103, which it plans to evaluate in a Phase 1 trial to prevent Graft versus Host Disease (GvHD) in patients undergoing mismatched hematopoietic stem cell transplant. The company is developing additional pipeline programs to treat inflammatory bowel disease, Type 1 diabetes and multiple B-cell mediated autoimmune diseases.William Lis was appointed CEO and Director; Scientific Founder Maria Grazia Roncarolo, M.D., was appointed President and Head of R&D and Director; Tao Fu, MBA, and Katherine A. High, M.D., were appointed Independent Directors. 19/01/2024
